BioMarin seeks UK approval to begin trial of Batten disease drug

04/3/2013 | Pharmaceutical Business Review Online

BioMarin Pharmaceutical filed an application with the U.K. Medicines and Healthcare Products Regulatory Agency seeking approval to initiate a Phase I/II trial of BMN-190, an experimental drug for neuronal ceroid lipofuscinosis type 2, a form of Batten disease. The firm expects patient enrollment for the trial to begin this year.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA